Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 2 , ISSUE 2 ( July-December, 2012 ) > List of Articles

ORIGINAL ARTICLE

Azathioprine Toxicity in Inflammatory Bowel Disease

Ahmet Uyanikoglu, Filiz Akyuz, Fatih Ermis, Fatih Besisik, Binnur Pinarbasi, Sabahattin Kaymakoglu, Kadir Demir, Gungör Boztas

Citation Information : Uyanikoglu A, Akyuz F, Ermis F, Besisik F, Pinarbasi B, Kaymakoglu S, Demir K, Boztas G. Azathioprine Toxicity in Inflammatory Bowel Disease. Euroasian J Hepatogastroenterol 2012; 2 (2):59-62.

DOI: 10.5005/jp-journals-10018-1035

License: CC BY-NC 4.0

Published Online: 01-07-2012


Abstract

Background/aim: The aim of this study was to evaluate patients with inflammatory bowel disease (IBD) treated with azathioprine (AZA) and followed-up in our clinic to adverse effects. Materials and methods: We analyzed patients with IBD who were treated with AZA between April 1998 and April 2008 for adverse events. Results: Four hundred and seventeen patients that included 211 (50.6%) females (age, 38.63 ± 13.32 years) were evaluated. Two hundred and forty-two patients (58%) had ulcerative colitis, 159 (38.1%) patients had Crohn’s disease and 16 (3.8%) patients had undetermined colitis. Mean follow-up period was 42.5 ± 46 months (range, 6-288 months). One hundred and eighty-nine (45.3%) patients used AZA (66% in Crohn’s disease group, 32% in ulcerative colitis group). Mean AZA treatment period was 33.8 ± 32 months (range, 6-160 months). Discontinuing rate was 19.6% (37 cases). Causes of discontinuing AZA were as follows: Adverse events in 15 patients (bone marrow suppression in three, pancreatitis in two, hepatotoxicity in two, related malignancy in three and other events in five patients), inefficacy in 12 patients, postoperation in five patients and other causes in five patients. Major toxicity was seen in seven of 189 patients (3.7%). Conclusion: Half of IBD patients were using AZA and major toxicity and malignancy development rates during AZA treatment were low. AZA is a safe immunosuppressive agent in IBD patients.


PDF Share
  1. Siegel CA, Sands BE. Review article: Practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005;22:1-16
  2. Infliximab, azathioprine or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383-95
  3. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008;64:753-67
  4. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease. Digestive Liver Dis 2011;43:270-76
  5. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-57
  6. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 2005;40:52-55
  7. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol 2003;239:69-72
  8. Optimization of immunomodulatory treatment with azathioprine or 6- mercaptopurine in inflammatory bowel disease. Gastroenterol Hepatol 2007;30:511-16
  9. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 2005;21:443-47
  10. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review. Am J Gastroenterol 2008;103:1783-800
  11. Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007;13:1106-14
  12. Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther 2004;20:843-50
  13. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004;20:161-66.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.